EZH2 Promotes Multiple Myeloma Progression via STAT3 Pathway Activation.

Autor:	Wang Y; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Tian J; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Huang D; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Gao Y; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Lin H; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Liu L; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China., Wang A; Department of Oncology and Hematology, Leshan People's Hospital, 614000 Leshan, Sichuan, China.
Jazyk:	angličtina
Zdroj:	Discovery medicine [Discov Med] 2024 Apr; Vol. 36 (183), pp. 721-729.
DOI:	10.24976/Discov.Med.202436183.68
Abstrakt:	Background: Multiple myeloma (MM) is a malignant disorder of plasma cells in the bone marrow. MM causes the clonal proliferation of terminally differentiated plasma cells and the accumulation of monoclonal plasma cells. The enhancer of zeste homolog 2 (EZH2) has been proven to play a significant role in disease development and could act on the signal transducers and activators of the transcription 3 (STAT3) signaling pathway. This pathway contributes to the pathogenesis and maintenance of malignancies. This study aimed to explore the effect of EZH2 on MM progression and the role of the STAT3 pathway in this process. The goal was to increase knowledge and provide further insights about the pathogenesis of MM and identify novel targets for potential therapies. Methods: The abnormal expression of EZH2 in MM cell lines was tested through real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) and western blot analysis. Based on the MM cell line H929, transfection was used to modify EZH2 expression, followed by the subsequent evaluation of induced alteration in STAT3 activation. The STAT3 phosphorylation activator colivelin and inhibitor stattic were used for promoting and inhibiting the STAT3 activation, respectively. Colony-forming assay, transwell migration assay, and flow cytometry were used to explore cell proliferation, cell migration, and cell apoptosis, respectively. Results: Both the EZH2 mRNA and protein were over-expressed in multiple MM cell lines including H929 ( p < 0.001), U266 ( p < 0.01), RPMI-8226 ( p < 0.01) and MM.1S ( p < 0.001). Increased EZH2 promoted cell proliferation ( p < 0.001) and migration ( p < 0.001) and simultaneously inhibited cell apoptosis ( p < 0.001), which could be reversed by inhibited STAT3 activation ( p < 0.001). In contrast, promoted STAT3 activation increased cell proliferation ( p < 0.001) and migration ( p < 0.001), while simultaneously inhibiting cell apoptosis ( p < 0.001), despite decreased EZH2 expression. Conclusions: The effect of EZH2 and STAT3 pathways on MM regulation was revealed and verified. EZH2 promoted the progression of MM cells by activating the STAT3 pathway. The EZH2 and STAT3 pathways could be potential targets for effective MM treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu